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Objective: Tourette’s syndrome is polygenic and highly her-
itable. Genome-wide association study (GWAS) approaches
are useful for interrogating the genetic architecture and de-
terminants of Tourette’s syndrome and other tic disorders.
The authors conducted a GWAS meta-analysis and probed
aggregated Tourette’s syndrome polygenic risk to test whether
Tourette’s and related tic disorders have an underlying shared
genetic etiology and whether Tourette’s polygenic risk scores
correlate with worst-ever tic severity and may represent a
potential predictor of disease severity.
Methods: GWAS meta-analysis, gene-based association,
and genetic enrichment analyses were conducted in 4,819
Tourette’s syndrome case subjects and 9,488 control sub-
jects. Replication of top loci was conducted in an indepen-
dent population-based sample (706 case subjects, 6,068
control subjects). Relationships between Tourette’s poly-
genic risk scores (PRSs), other tic disorders, ascertainment,
and tic severity were examined.
Results: GWAS and gene-based analyses identified one
genome-wide significant locus within FLT3 on chromosome
13, rs2504235, although this association was not replicated
in the population-based sample. Genetic variants spanning
evolutionarily conserved regions significantly explained
92.4% of Tourette’s syndrome heritability. Tourette’s-
associated genes were significantly preferentially expressed
in dorsolateral prefrontal cortex. Tourette’s PRS significantly
predicted both Tourette’s syndrome and tic spectrum dis-
orders status in the population-based sample. Tourette’s PRS
also significantly correlated with worst-ever tic severity and
was higher in case subjects with a family history of tics than
in simplex case subjects.
Conclusions: Modulation of gene expression through non-
coding variants, particularly within cortico-striatal circuits, is
implicated as a fundamental mechanism in Tourette’s syn-
drome pathogenesis. At a genetic level, tic disorders re-
present a continuous spectrum of disease, supporting the
unification of Tourette’s syndrome and other tic disorders in
future diagnostic schemata. Tourette’s PRSs derived from
sufficiently large samples may be useful in the future for
predicting conversion of transient tics to chronic tic disor-
ders, as well as tic persistence and lifetime tic severity.
Am J Psychiatry 2019; 176:217–227; doi: 10.1176/appi.ajp.2018.18070857
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Tourette’s syndrome is a complex neuropsychiatric disorder
that occurs along a phenotypic spectrum that also includes
chronic (persistent)motor or vocal tic disorder (chronic tics)
and transient (provisional) tic disorder (1). Although Tou-
rette’s syndrome is highly heritable (2), variants in known
Tourette’s risk genes (e.g., CNTN6, NRXN1, SLITRK1, HDC,
and CELSR3) account for less than 2% of affected individ-
uals (3–6). Tourette’s syndrome is highly polygenic, with a
demonstrated role for multiple common genetic variants of
small effect distributed widely across the genome (7). Thus,
genome-wide association studies (GWASs) (8) will be of
benefit in further elucidating the underlying genetic etiology
of the disorder.
To date, only one Tourette’s GWAS has been published (9).
Although no single-nucleotide polymorphisms (SNPs) met
criteria for genome-wide significance (p,531028), in ag-
gregate, the top SNPs (p values,131023) were enriched for
expression quantitative trait loci (eQTLs) in the frontal cortex
and for methylation quantitative trait loci (mQTLs) in the
cerebellum, indicating that a significant proportion of these
variants have biological relevance to Tourette’s syndrome,
and perhaps also to other tic disorders. However, as with
other neuropsychiatric disorders, much larger sample sizes
are needed to elucidate the disorder’s genetic underpinnings.
Here, we report the results of a GWAS meta-analysis from
the Psychiatric Genomics Consortium (PGC) Tourette Syn-
dromeWorkgroup in a sample that is nearly four times larger
than the initial GWAS (9). We also probed aggregated
Tourette’s syndrome polygenic risk to test two specific hy-
potheses: whether Tourette’s and related tic disorders have
an underlying shared genetic etiology and whether Tou-
rette’s polygenic risk scores correlate with worst-ever tic




The primary GWAS meta-analysis consisted of four Euro-
pean ancestry (EU) GWAS data sets: 1) 969 case subjects and
3,923 ancestry-matched control subjects from the initial
Tourette’s syndrome GWAS (GWAS1) (9); 2) 2,711 additional
EU Tourette’s case subjects (4) and 3,762 ancestry-matched
control subjects (GWAS2); 3) Tourette’s probands from
GWAS1 and one or more of their Tourette’s-affected fam-
ily members (10) (N=548) plus 597 ancestry-matched con-
trol subjects (GWAS2 FAM); and 4) 591 independent EU
Tourette’s probands from the Tourette International Col-
laborative Genetics (TIC) study (11) and 1,206 unselected
ancestry-matched control subjects. Genotyping details are
provided in Tables S1 and S2 in the online supplement.
GWAS1. A total of 1,285 EU case subjects (number of cases
from the GWAS1 paper) were collected from Tourette’s
syndrome specialty clinics in the United States, Canada,
the United Kingdom, and the Netherlands or through
recruitment from the membership of the Tourette Associa-
tion of America. Tourette’s diagnoses were based on DSM-
IV-TR criteria plus observation of tics by an experienced
clinician. After removing the subjects who were relatives or
duplicates of subjects in GWAS2 or GWAS2 FAM, a total of
969 cases were retained for analysis. A total of 3,923 control
subjects were identified primarily from previously genotyped
unselected population control subjects and were ancestry-
matched to the case subjects (9).
GWAS2. A total of 2,871 EU case subjects with DSM-5
Tourette’s syndrome were identified by e-mail or online re-
cruitment combined with validated, web-based phenotypic
assessments (12, 13) (N=1,264) or from Tourette’s syndrome
specialty clinics in the United States, Canada, and Europe
(N=1,607) (see the Supplemental Methods section in the
online supplement). All subjects were genotyped at the
UCLA Neuroscience Genomics Core. After quality control,
2,711 case subjects were retained for analysis.
GWAS2 FAM. The family sample consisted of 548 probands
and first-degree relatives with Tourette’s syndrome from
207 independent families (10). A total of 175 probands came
from the original Tourette’s GWAS1 sample; these case
subjects were removed from the GWAS1 analysis along with
ancestry-matched control subjects and reanalyzed with the
family-based sample. Thirty-two Tourette’s probands and
341 additional Tourette’s-affected family members (total
N=373) were genotyped along with the GWAS2 case-control
sample.A totalof 597ancestry-matchedcontrol subjectswere
selected from a pool of previously genotyped control sub-
jects (see the Supplemental Methods section in the online
supplement).
TIC. The TIC Genetics sample consisted of 591 probands,
579ofwhommetDSM-5criteria forTourette’s syndromeand
12 ofwhommet criteria forDSM-5 chronicmotor or vocal tic
disorder (see Tables S1 and S2 in the online supplement).
Control subjects. A total of 6,920 EU control subjects were
obtained from cohorts of previously genotyped unselected
population control subjects for the GWAS2, GWAS2 FAM,
and TIC Genetics analyses; an additional 595 EU control
subjects were genotyped with the Tourette’s case subjects at
the UCLA Neuroscience Genomics Core (see Table S1 and the
Supplemental Methods section in the online supplement).
deCODE. An independent case-control replication sample
from Iceland (deCODE genetics, Reykjavik) consisted of
706 Icelandic Tourette’s syndrome case subjects and 466
case subjects with other tic disorders (chronic tics or unspec-
ified tic disorder) (see the Supplemental Methods section
in the online supplement). A total of 127,164 unscreened
population-matched control subjects were also available, of
whom 6,068 were screened and reported no lifetime sub-
clinical motor or vocal tics. Case and control subjects were
218 ajp.psychiatryonline.org Am J Psychiatry 176:3, March 2019
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genotyped at deCODE on Illumina SNP arrays (see the
Supplemental Methods section).
Participants age 18 and older provided written informed
consent; individuals under 18 gave assent, and parental
permission was obtained. The study was approved by the
human subjects committees at all participating sites.
Quality Control
Genotyping quality controlwas performed inPLINK, version
1.9 (14) (see the Supplemental Methods section). Duplicates
and relatives were identified using genome-wide identity-
by-descent estimates, and one member of each duplicate
or relative pair was removed from the case-control sample.
Relative pairs in which both individuals had a Tourette’s
diagnosis were removed from the case-control sample and
moved to the family-based analysis.
Population stratification was assessed through multi-
dimensional scaling (MDS) analysis; individuals of non-
European ancestry and extreme outliers on each of the
MDS components were removed (see the Supplemental
Methods section and Figure S1 in the online supplement).
Case-control matching was verified across all MDS compo-
nents. The final post–quality control GWAS2 sample con-
tained 2,711 case subjects, 3,762 ancestry-matched control
subjects, and 550,550 SNPs; the final GWAS2 FAM sam-
ple contained 548 case subjects and family members, 597
ancestry-matched control subjects, and 236,748 SNPs. The
final TIC sample included 591 case subjects, 1,206 ancestry-
matched control subjects, and 581,774 SNPs (see Table S2
in the online supplement).
Imputation and Genome-Wide Association
SNP imputation was conducted on all genotype data for the
primary meta-analyses using the 1000 Genomes Project
phase 1 integrated haplotypes (December 2013 release,
with singleton sites removed) as the reference panel (15).
SHAPEIT was used to phase genotype data, followed by
imputation with IMPUTE, version 2. SNPs with INFO
score ,0.6 or certainty ,0.9 were excluded.
Genome-wide association tests were performed on the
imputed dosage data of the GWAS2 and TIC samples sepa-
rately in PLINK 1.9, using logistic regression under an ad-
ditive model with the first four MDS components and any
additionalMDScomponents associatedwithTourette’s case-
control status at p,0.05 included as covariates. A linear
mixed model was used for the GWAS2 FAM association
analysis in MMM, version 1.0 (16), to control for familial
relatedness. GWAS1 samples were reimputed as described
above; association tests were performed in four ancestry-
based strata: nonisolate European (GWAS1_EU), Ashkenazi
Jewish (GWAS1_AJ), French Canadian (GWAS1_FC), and
GWAS1 TIC (GWAS1_TIC) (see Table S2).
A primary GWAS meta-analysis was conducted on the
GWAS1, GWAS2, GWAS2 FAM, and TIC data sets using the
inverse-variance method inMETAL (17). Heterogeneity was
assessed with Cochran’s I2 statistic. The genomic control
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a Panel A is a quantile-quantile plot of observed versus expected 2log10(p) values from the primary genome-wide association study (GWAS) meta-
analysis. The 95% confidence interval of expected values is indicated in gray. The genomic control l value is 1.072, and the l1000 value is 1.011
for single-nucleotide polymorphisms (SNPs) with minor allele frequency.0.01, INFO score (measurement of imputation quality).0.6, and certainty
.0.9.PanelB isaManhattanplotofallfinalgenotypedandimputedSNPs intheprimaryTourette’s syndromeGWASmeta-analysis.Theupperhorizontal line
indicates the genome-wide significance threshold of 531028, and the lower horizontal line indicates the suggestive threshold of 1.031025.
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factor (l) was calculated for each individual GWAS and for
the overall meta-analysis using all SNPs with minor allele
frequency (MAF) .0.01 to identify residual population
stratification or systematic technical artifact (see Figure S2
in the online supplement). GWAS summary statistics were
subjected to linkage disequilibrium (LD) score regression
(LDSC) analyses on high-quality common SNPs (INFO
score.0.9 and MAF.0.01) to examine the LDSC intercept
as a more specific measure of inflation of the GWAS test
statistic (18) due to residual artifact or stratification. The
genome-wide significance threshold for the GWAS (19, 20)
was set at a p value of 5.031028.
Heritability Estimation
Tourette’s syndrome SNP-based heritability was estimated
on the liability scale, assuming a population prevalence of
0.8% (21), using both LDSC (18) and, in the GWAS1 and
GWAS2 samples after excluding Ashkenazi Jewish and
French Canadian samples, genotype-level data in a linear
mixed model framework (7). To compare the relative
polygenic burden of Tourette’s samples collected with
different ascertainment methods, the Tourette’s GWAS1
and GWAS2 data sets were separated into three groups:
GWAS1 case subjects (25% from affected sibling-pair
families) (10); GWAS2 case subjects recruited through
Tourette’s syndrome specialty clinics; and GWAS2 case
subjects recruited via e-mail from the membership of
the Tourette Association of America and assessed with a
web-based phenotyping instrument (12). After additional
stringent quality control of SNPs and samples (see the
Supplemental Methods section), the SNP-based herita-
bility of each ascertainment group was estimated both
separately and jointly.
Partitioned heritability analyses were conducted using
LDSC to evaluate enrichment of Tourette’s SNP-based heri-
tability from different functional annotation classes and
different cell or tissue types (22) and to examine genetic cor-
relations between the GWAS1, GWAS2, and TIC data sets.
Targeted Replication
The population-based deCODE samples were used 1) to in-
dependently replicate the 39 top LD-independent SNPs
(r2,0.2 and MAF.0.01; p,1.031025) in the primary meta-
analysis, followed by a sign test to examine consistency in the
direction of effects in these top SNPs across the two data sets, as
well as a targeted meta-analysis of these 39 SNPs using the
inverse-variance method (see the Supplemental Methods
section); and 2) to examine the genetic relationships between
Tourette’s and other tic disorders through polygenic risk
score (PRS) analyses (see the Supplemental Methods section)
(23). Logistic regressions were performed to test the pre-
diction power of PRS for Tourette’s syndrome and tic dis-
order case subjects comparedwith control subjects, adjusted
by sex, year of birth, and the first 20 principal components (24).
Polygenic Risk Score Analyses
Genome-wide Tourette’s PRSs adjusted for ancestry prin-
cipal components (aPRSs) were generated for all subjects in
the primary meta-analysis using the entire distribution
(GWAS p#1) of LD-independent SNPs (r2,0.2) through a
cross-validation approach (23) and used to examine the re-
lationship between Tourette’s aPRS and ascertainment,
family history of Tourette’s or chronic tics, and lifetime
worst-ever tic severity (YaleGlobalTicSeverity Scale total tic
score [tic severity], range 0–50) (see the Supplemental
Methods section).
TABLE 1. Top 10 linkage disequilibrium–independent loci in the primary Tourette’s syndrome GWAS meta-analysisa
Primary Meta-Analysis
SNP CHR BP A1/A2 INFO Score MAF Odds Ratio p
rs2504235 13 28,612,886 A/G 0.99 0.38 1.16 2.1E–08
rs191044310 10 23,705,451 A/T 0.83 0.02 0.54 1.5E–07
rs13407215 2 161,544,891 T/C 1.00 0.02 2.21 1.9E–07
rs2708146 2 58955953 G/A 1.009 0.46 0.88 3.2E–07
rs1906252b 6 98,550,289 A/C 1.00 0.49 0.88 7.0E–07
rs12459560 19 52,318,380 T/G 0.98 0.15 1.19 8.2E–07
rs117648881 8 113,581,898 A/G 0.77 0.02 0.59 8.8E–07
rs6670211 1 29,576,784 A/C 1.00 0.47 0.88 1.4E–06
rs72853320 6 36,623,338 A/G 1.00 0.13 1.20 1.7E–06
rs73205493 4 2,460,571 T/C 0.89 0.34 1.16 1.8E–06
a For each linkage disequilibrium (LD) independent locus, the minor allele frequency (MAF), odds ratio, and association p value of the
index single-nucleotide polymorphism (SNP) is presented for the primary Tourette’s syndromeGWASmeta-analysis of 4,819 Tourette’s case
subjects and 9,488 control subjects, for the targeted replication in the independent deCODE sample (706 Tourette’s case subjects and 6,068
control subjects), and for the meta-analysis of these two data sets. Complete annotation of these SNPs and all SNPs with association p
values,1.0310–5 is provided in Tables S3 and S4 in the online supplement. CHR=chromosome; BP=hg19 position; A1=minor allele; A2=major
allele; INFOscore=measurementof imputationquality; LDblock=chromosomal regionswhere SNPs are in linkagedisequilibriumwith the index
SNP (r2.0.2) with association p value,0.05.
b rs1906252 and the LD block defined by r2.0.2 were reported to be associated with other disorders and measures, including bipolar
disorder, educational attainment, gut microbiota, and intelligence.
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Gene-Based and Gene Set Enrichment Analysis
Gene-based tests and competitive gene set enrichment
analyses were conducted in MAGMA (25) (see the Supple-
mental Methods section). Gene-based test statistics were
derived using association summary statistics for all SNPs
assigned to each gene including 50-kb flanking regions af-
ter accounting for LD, and p values were adjusted with a
Bonferroni correction for 18,079 genes genome-wide. Gene-
based statistics were then analyzed for tissue expression
enrichment in 53 distinct human tissues from 714 donors
using GTEx RNA-seq data (26), and Bonferroni correction
was applied for 53 tissue types (p=0.05/53=9.431024).
Tested gene sets included 107 probable autism spectrum
disorder susceptibility genes from exome sequencing studies
(27), evolutionarily constrained genes (probability of loss-of-
function intolerance score .0.9), previously identified con-
strained genes harboring deleterious rare variants (large copy
number variants or de novo loss-of-function mutations) in
Tourette’s case subjects (4, 5), and all Gene Ontology terms
from the Molecular Signatures Database, version 6.0
(MSigDB 6.0) (see the Supplemental Methods section).




The final GWAS meta-analysis consisted of 8,265,319 SNPs
in 4,819 Tourette’s syndrome case subjects and 9,488 control
subjects. No evidence of residual population stratification
or systematic technical artifact was observed in any of the in-
dividual data sets (see Figure S2 in the online supplement)
or in the final meta-analysis (l=1.072, l1000=1.011) (Figure
1). LDSC indicated that 86% of the observed test statistic
inflation was attributable to an underlying genome-wide
polygenic signal (see Figure S3 in the online supplement).
PRS analyses in each individual GWAS data set, derived
using a leave-one-out approach, as well as in the deCODE
sample, indicated genetic homogeneity across all contributing
data sets (see Figures S4 and S5 in the online supplement).
The top SNP in the GWAS meta-analysis, rs2504235, lo-
cated on chromosome 13q12.2, surpassed the genome-
wide significance threshold (odds ratio=1.16, p=2.131028)
(Table 1; see also Figure S6 in the online supplement).
rs2504235 lies within an intron of FLT3, encoding FMS-like
tyrosine kinase 3. No other SNPs achieved genome-wide
significance, although rs1933437, a common FLT3 missense
variant (Thr227Met) that lies 11.4 kb away from and is in
strongLDwith rs2504235 (r2=0.93), had ap value of 8.231028
(see Table S3 in the online supplement). Across the genome,
39 LD-independent index SNPs with p values,131025 were
identified by LD pruning (r2,0.2) followed by conditional
association analyses controlling for the most significant
SNP within each 2-Mb window and manual inspection of re-
gional association plots to confirm the presence of sup-
porting statistical evidence of association from nearby SNPs
(see Tables S3 and S4 in the online supplement). The top 10
LD-independent index SNPs are presented in Table 1.
Targeted Replication
The 39 LD-independent index SNPs with p,131025 were
investigated for replication in the deCODE sample (706 case
subjects, 6,068 control subjects). None of the individual SNPs
were replicated after Bonferroni correction (replication
threshold for 39 tests, p,0.0013) (see Table 1; see also Table
S4 in the online supplement); 23 of 39 putative Tourette’s
syndrome risk alleles had the same direction of effect, al-
though this was not statistically significant (binomial two-
way sign test, p=0.34).
Meta-analysis restricted to these 39 SNPs was conducted
using summary statistics from the primary meta-analysis
and the deCODE data with the inverse variance method in
METAL. No SNP achieved genome-wide significance; the SNP
with the lowest p value was rs13407215, on chromosome
2(p=1.931027). rs2504235wasnotgenome-widesignificant in
this analysis (p=2.431027) (see Table 1; see also Table S4).
deCODE Sample Primary and deCODE Sample
MAF Odds Ratio p Odds Ratio p LD Block Genes
0.32 0.94 0.50 1.14 2.4E–07 28591318..28659473 FLT3
0.0024 2.27 0.25 0.56 5.9E–07 23661149..23815120 OTUD1
0.0001 0.02 0.85 2.21 1.9E–07 160090844..162912453 Multiple genesc
0.48 0.98 0.75 0.89 8.0E–07 58847953..59094609 LINC01122
0.50 0.90 0.17 0.88 2.8E–07 98214814..98664414 MIR2113
0.16 1.08 0.45 1.18 9.1E–07 52266072..52606936 Multiple genesd
0.01 0.72 0.32 0.60 6.2E–07 113581898..114612903 CSMD3, MIR2053
0.42 0.94 0.45 0.89 1.5E–06 29188630..29607279 EPB41, MECR, OPRD1, PTPRU, SRSF4,
TMEM200B
0.12 0.88 0.28 1.17 2.2E–05 36375986..36658092 CDKN1A, KCTD20, MIR3925, PANDAR,
PXT1, RAB44, SRSF3, STK38
0.35 1.08 0.34 1.15 1.6E–06 2407263..2481088 LOC402160, RNF4, ZFYVE28
c AHCTF1P1, BAZ2B, CD302, DPP4, ITGB6, LOC643072, LOC100505984, LOC100996579, LOC101929512, LY75, LY75-CD302, MARCH7, MIR4785, PLA2R1,
PSMD14, RBMS1, SLC4A10, TANC1, TANK, TBR1, WDSUB1.
d FPR1, FPR2, FPR3, HCCAT3, LOC101928571, ZNF350, ZNF432, ZNF577, ZNF613, ZNF614, ZNF615, ZNF616, ZNF649, ZNF841.
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Heritability and PRS Analyses
Tourette’s syndrome SNP-based heritability (h2g) was esti-
mated in the primary GWAS meta-analysis using LDSC
(h2g=0.21, SE=0.024, p,2.0310
216). Pairwise genetic cor-
relations across the three independent case-control data sets
(GWAS1, GWAS2, TIC) confirmed a significant shared
polygenic architecture (GWAS1-GWAS2: rg=0.86, SE=0.21,
p=3.931025; GWAS1-TIC: rg=0.84, SE=0.30, p=4.5310
23;
GWAS2-TIC: rg=0.93, SE=0.26, p=4310
24).
Because the previous estimate of Tourette’s syndrome
h2g from the first Tourette’s GWAS (linear mixed model,
h2g=0.58, SE=0.09) (7) was significantly higher than that
observed in this study, additional heritability analyses were
conducted in the individual data sets, stratified on ascer-
tainment status, using linear mixed models (LMM) (7)
(Table 2). These analyses confirmedboth thehighSNP-based
heritability of the sibling-pair-enriched Tourette’s GWAS1
sample (GWAS1-LMM: h2g=0.56, SE=0.10; p=1.2310
29) and
the lowerheritability of the larger GWAS2 sample (GWAS2-
LMM: h2g=0.29, SE=0.04; p=5.5310
214).
To explore the hypothesis that the lower heritability of
the Tourette’s GWAS2 sample may have arisen from the
inclusion of Tourette’s case subjects diagnosed in the com-
munity and ascertained using a validated web-based screen
(12, 13), the GWAS2 case-control sample was divided into
clinic-based and web-based case subjects, and the LMM-
based heritability analyses were repeated. Contrary to the
predicted hypothesis, both subsets had the same heritability
(GWAS2-clinic: h2g=0.29, SE=0.07; p=1.2310
29; GWAS2-
web: h2g=0.28, SE=0.10; p=1.2310
29) (see Table 2).
Tourette’s Syndrome PRS in Multiplex Versus
Simplex Families
Since a large proportion of Tourette’s GWAS1 case subjects
werederived fromaffected sibling-pair families,whichmight
be expected to harbor higher Tourette’s syndrome polygenic
risk than case subjects fromsimplex familieswithout affected
first-degree relatives, we examined the relationship between
ancestry-adjusted PRS (aPRS) in case subjects from multiplex
families (positive forfirst-degree
relative family history) com-
pared with simplex families
(negative for first-degree rela-
tive family history) (see the Sup-
plemental Methods section).
Because multiplex Tou-
rette’s syndrome case subjects
with a Tourette’s-affected
parent or sibling (N=417)
demonstrated mean aPRSs
similar to Tourette’s GWAS
case subjects with a chronic
tic-affected parent or sibling
(N=111) (F=0.12, df=1, p=0.73),
we combined both Tourette’s
case groups for further anal-
yses (Tourette’s/chronic tic family history positive case sub-
jects, N=528). The combined Tourette’s/chronic tic multiplex
case subjects had a significantly higher mean aPRS compared
with the aPRS from Tourette’s/chronic tic simplex case
subjects (N=346) (F=4.90, df=1, p=0.027), confirming that
multiplex case subjects were enriched for Tourette’s poly-
genic risk (see Figure S7 in the online supplement).
Tourette’s Syndrome PRS and Tic Severity
Given the strong enrichment of Tourette’s aPRS in case
subjects from multiplex families, Tourette’s/chronic tic
family history positive Tourette’s case subjects were exam-
ined next to test whether Tourette’s aPRS may serve as a
predictor of higher disease severity in these case subjects
(see the Supplemental Methods section). After adjustment
for residual population stratification using the first four prin-
cipal components, higher Tourette’s aPRS was significantly
correlated with increased worst-ever tic severity (b=0.93,
SE=0.42, p=0.026), with every one-standard-deviation in-
crease in Tourette’s aPRS corresponding to a 0.93-point
increase in worst-ever tic severity (total range, 0–50).
Tourette’s Syndrome and Tic Spectrum Phenotypes
Given the hypothesis that Tourette’s and other tic disorders
represent a phenotypic spectrum with a shared genetic eti-
ology, Tourette’s PRS derived from the GWASmeta-analysis
was compared in Tourette’s and tic spectrum case subjects in
the Icelandic deCODE sample (Figure 2; see also Figure S5
in the online supplement). Tourette’s PRS was significantly
higher in both deCODE Tourette’s case subjects and tic
spectrumcase subjects comparedwith control subjects (odds
ratio=1.33, p=5.331029, and odds ratio=1.20, p=5.231024,
respectively), explaining 0.78% and 0.42% of the pheno-
typic variance, respectively. Direct comparison between
case groups confirmed that deCODE Tourette’s case subjects
carried a higher Tourette’s syndrome polygenic burden
than subjects with other tic spectrum disorders (odds ra-
tio=1.14, p=0.05), representing an excess 0.37% of the phe-
notypic variance (see Figure 2).
TABLE 2. Single-nucleotide polymorphism–based heritability estimates derived using a linear
mixed model method for the Tourette’s syndrome GWAS1 and GWAS2 European ancestry
case-control samplesa
Case Subjects Control Subjects
Sample N % N % V(G)/Vp_Lb SE p
GWAS1 559 14 3,400 86 0.565 0.096 1.2310–9
GWAS2c 2,146 46 2,564 54 0.288 0.040 5.5310–14
GWAS2c web-based 934 27 2,564 73 0.294 0.067 2.4310–6
GWAS2c clinic-based 1,098 30 2,564 70 0.284 0.059 4.0310–7
a Heritability estimates were calculated first for the entire Tourette’s syndrome GWAS1 and GWAS2 samples; sub-
sequently, the Tourette’s GWAS2 sample was separated into two subsets based on case ascertainment method
(clinic-based versus web-based). The TIC Genetics case-control sample was not large enough to obtain an in-
dependent heritability estimate using a linear mixed model approach. All heritability estimates are presented on the
liability scale. Subjects from European population isolates (Ashkenazi Jewish and French Canadian) were excluded
from the linear mixed-model analyses.
b Tourette’s syndrome prevalence was defined as 0.8%.
c GWAS2 family data were not included in the heritability estimate.
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Enrichment of Tourette’s Syndrome Heritability by
Functional Annotation and Gene Expression
Tourette’s syndrome SNP-based heritability (h2g) from the
GWAS meta-analysis was also used as a genome-wide probe
to test whether aggregated Tourette’s syndrome genetic risk
may be concentrated either in 52 specific functional genomic
elements (e.g., promoters, enhancers, epigeneticmarks) or in
gene expression patterns from 10 grouped tissue or cell types
using partitioned LDSC (22). Evolutionarily conserved SNPs
(2.6% of all SNPs) were enriched 16.5-fold for Tourette’s
h2g, accounting for 42.3% of Tourette’s syndrome heritabil-
ity (Pr[h2g]/Pr[SNPs]=16.5, SE=5.3, p=3.6310
23, not signifi-
cant after correction). A parallel analysis including these
evolutionarily conserved SNPs plus 500-bp flanking windows
(33% of all SNPs) was enriched 2.8-fold for Tourette’s h2g and
accounted for 92.4% of Tourette’s syndrome heritability
(Pr[h2g]/Pr[SNPs]=2.80, SE=0.46, p=1.0310
24; p=0.005 after
correction) (see Figure S8 in the online supplement). No other
genomic annotations were significantly enriched for Tou-
rette’s SNP-based heritability. In the cell-type analysis, sig-
nificant enrichment was found only for CNS cell types, with
62.7% of Tourette’s syndrome heritability contributed by
14.8% of SNPs (p=4.231028; p=4.231027 after correction)
(see Figure S9 in the online supplement).
Gene-Based Association and Enrichment Analyses
Gene-based association and enrichment tests were per-
formed using meta-analysis summary statistics in MAGMA
and gene expression data in GTEx (https://www.gtexportal.
org/home/). FLT3 was identified with genome-wide signif-
icant association after correcting for 18,079 gene tests
(p=8.931027) (see Figure S10 in the online supplement). The
most significant SNP in the FLT3 locus, rs2504235, was the
only SNP surpassing genome-wide significance threshold in
the primary meta-analysis and was significantly associated
with FLT3 expression level both in cerebellum (p=6.53
10210) and cerebral cortex (p=2.6310211). No gene set was
significantly associated with Tourette’s syndrome after
Bonferroni correction. In the gene expression enrichment
analyses of 53 adult human tissues, only dorsolateral pre-
frontal cortex (Brodmann’s area 9) demonstrated significant
enrichment of Tourette’s-associated genes after correction
(b=0.023, SE=0.0069, p=1.231024) (Figure 3; see also the
Supplemental Methods section).
DISCUSSION
Tourette’s syndrome has long been conceptualized as part of
a spectrumof developmental tic disorders,with transient tics
at one end (1) and severe Tourette’s syndrome with multiple
psychiatric comorbidities at the other. However, until re-
cently, potential biological relationships between the various
tic disorders were unknown, as were the underlying ge-
netic contributions to tic severity. The results of this study
further illuminate the genetic architecture of Tourette’s
syndrome and its relationships to phenotypic expression.
First, the PRS analyses probing the genetic architecture of tic
disorders in the population-based Icelandic sample dem-
onstrate that individuals with Tourette’s syndrome share the
same underlying polygenic risk as those with other tic dis-
orders. Furthermore, the observation that Tourette’s syn-
drome case subjects have a significantly higher mean PRS
than those with non-Tourette’s tic disorders provides evi-
dence for a liability spectrum of genetic risk within tic dis-
orders. Lastly, within Tourette’s syndrome case subjects, the
finding that higher Tourette’s PRSwas associated with greater
tic severity also builds on our previous analyses demonstrat-
ing a relationship between higher Tourette’s PRS and the
presence of complex symmetry and socially inappropriate
tics (28). These relationships, although hypothesized on the
FIGURE 2. Density plot demonstrating the distribution of
Tourette’s syndrome polygenic risk scores (PRSs) in population-
based Icelandic Tourette’s case subjects, tic disorder case















Tic-negative population control subjects
Population control subjects
Tic disorder case subjects
Tourette’s syndrome case subjects
a The x-axis represents the scaled Tourette’s syndrome PRS score, where
an increase of one standard deviation in PRS score doubles Tourette’s
syndrome risk. The dashed lines correspond to the mean of the re-
spective groups. The black dotted line toward the right corresponds to
one standard deviation from the population mean.
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basis of clinical observations, have not previously been dem-
onstrated at the molecular genetic level, and ultimately they
will help provide insight into the molecular mechanisms of
tic development and expression.
These observations have direct biological and clinical
relevance. First, they support previous efforts to conceptu-
alize Tourette’s and chronic tics as a unified condition and
to combine them into a single tic spectrum disorder in fu-
ture diagnostic schemas (1). Although traditionally separated
clinically into distinct disorders, chronic/persistent tic dis-
orders, whether consisting of motor tics, vocal tics, or both,
appear to be due to the same underlying genetic causes.
Second, while the small proportion of explained variance in
worst-ever tic severity is a limitation of the present study,
work in other polygenic psychiatric disorders, such as schizo-
phrenia, has repeatedly demonstrated that as GWAS sample
sizes increase, the proportion of phenotype explained by
polygenic risk scores increases markedly (29). It is therefore
possible that in the future, Tourette’s PRS may be a potential
candidate for predicting both conversion to chronic tics in
the 20%225% of children who present with transient tics (1)
and, at the other end of the phenotypic spectrum, tic persis-
tence and lifetime tic severity in those with Tourette’s syn-
drome. Finally, particularly important in the context of the
very large sample sizes required for the success of GWAS
efforts, our results suggest that future genetic association
studies may benefit from expanding disease definitions to
include case subjects with both Tourette’s and chronic tics.
Our genome-wide cell and tissue-based enrichment analyses
implicate modulation of gene expression through noncoding
variants as a fundamental mechanism in the pathogenesis of
Tourette’s syndrome. All of the top tissues in the enrichment
analyses were derived from brain, although dorsolateral pre-
frontal cortex (Brodmann’s area9)was the only tissue inwhich
eQTL enrichment surpassed Bonferroni correction. The five
tissues with the strongest eQTL enrichment (frontal cortex,
caudate, putamen, nucleus accumbens, and cerebellum) all
represent key nodes within the cortico-striatal and cortico-
cerebellar circuits that have been implicated in Tourette’s
pathophysiology (1). These results support the hypothesis that
Tourette’s syndrome is a developmental circuit disorder af-
fecting motor, cognitive, and behavioral control (as manifested
by tics and attention-deficit and obsessive-compulsive symp-
toms) and suggest that future GWAS analyses in larger data
sets should aid in identifying not only the individual genes
underlying susceptibility to Tourette’s syndrome but also core
pathways in the development and regulation of these circuits
that could serve as targets for modulation-based therapies.









































































































































































































































































































































































































































































































































































































































aGene-based test statistics were derived from Tourette’s syndrome GWAS meta-analysis summary statistics on single-nucleotide polymorphisms
(SNPs) with minor allele frequency .0.01 and INFO score (measurement of imputation quality) .0.9. SNPs were assigned to genes based on their
position according to NCBI Build 37.3 and 50-kb upstream and downstream flanking regions. Summary statistics on 18,079 genes were generated.
The European panel of the 1000 Genomes data (phase 3) was used as the reference panel to account for linkage disequilibrium. GTEx (version 7)
RNA-seq data expression values were log2 transformed with a pseudo-count of 1 after Winsorization at 50, and the average was taken per
tissue. Fifty-three specific tissue types were tested separately in MAGMA (23). The significance threshold for the tissue-specific test was
calculated using the Bonferroni method (alpha=0.05/53, p,9.4331024). Frontal cortex (Brodmann’s area [BA] 9), corresponding to dorsolateral
prefrontal cortex, demonstrated significant enrichment of Tourette’s-related genes after correction for multiple hypothesis testing.
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Limitations
This study has several potential limitations, the most sig-
nificant of which is the sample size. Although this is the
largest Tourette’s syndrome GWAS conducted to date, our
sample of fewer than 5,000 case subjects is clearly not
yet sufficient to identify definitive Tourette’s susceptibility
variants, as demonstrated by the failure of the top GWAS
SNP to replicate in the deCODE sample. Additional potential
limitations are also related to sample size, including reduced
power to examine additional clinical variables of interest,
such as age at onset of tics and co-occurring psychiatric
illnesses such as obsessive-compulsive disorder and atten-
tion deficit hyperactivity disorder. However, we anticipate
that most, if not all, of these limitations can be resolved by
substantial increases in the number of Tourette’s syndrome
case subjects collected for GWAS, an effort that is currently
under way.
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